ACE2 News and Research

RSS

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Researchers aimed to understand the relationship between the SARS-CoV-2 receptor-binding domain and both human receptors and therapeutic targets.

3 Feb 2022

Evaluating effects of D614G and P681R/H mutations on SARS-CoV-2 VOCs

Researchers evaluate how the D614G and P681H mutations alter the attributes of SARS-CoV-2 VOCs.

3 Feb 2022

Relationship between SARS-CoV-2 neurotropism and Alzheimer's disease

In a new study, researchers evaluated the neurotropism of SARS-CoV-2 and its impact on COVID-19 patients with and without neurological disorders like Alzheimer's disease.

3 Feb 2022

Exploring human milk oligosaccharides as a method of COVID-19 prevention

New research was conducted to ascertain whether antiviral and immunomodulatory activities of human milk oligosaccharides can be efficacious in the prevention and treatment against COVID-19.

3 Feb 2022

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

Researchers evaluated the initial three days of SARS-CoV-2 infection via scRNAseq dataset in humanized in vitro model.

3 Feb 2022

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Researchers demonstrate that SARS-CoV-2 RBD-based nanoparticle vaccine induces neutralizing antibodies against SARS-CoV-2 variants.

2 Feb 2022

SARS-CoV-2 omicron variant shown to replicate less efficiently in human lungs

A new study revealed that the omicron variant replicates more effectively in the human bronchus than other SARS-CoV-2 variants, yet this new variant has lower replication competence in the lungs.

2 Feb 2022

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Researchers from China summarized the representative structures of SARS-CoV-2 proteins and discussed the development of novel therapeutic agents for targeting these proteins to treat and prevent COVID-19.

2 Feb 2022

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

A large multinational group of researchers has shown how the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained exceptional immune evasion properties but also a much lower propensity to enter cells such as those in lung alveoli, resulting in its reduced pathogenicity. Their paper is currently released as an unedited version of the manuscript prior to publication in the journal Nature.

1 Feb 2022

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Exogenous trypsin treatment boosts SARS-CoV-2 infection in Vero E6 cells and promotes viral multiplication in cultured cells.

1 Feb 2022

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

In a new study, a team of researchers assessed the neutralizing activity of XAV-19, a glyco-humanized polyclonal antibody derived from hyperimmunized animal hosts, against the SARS-CoV-2 Omicron variant.

1 Feb 2022

Illustrating the structural diversity of SARS-CoV-2 Omicron spike

In a new study, a team of researchers used cryo-electron microscopy to determine the spike (S) structures of the SARS-CoV-2 Omicron variant to understand how the mutations that alter its primary sequence impact S conformation.

1 Feb 2022

Exploring beta-coronavirus neutralization by vaccine-induced murine antibody WS6

In a new study, researchers evaluated the neutralizing antibody titers in mice vaccinated with messenger ribonucleic acid (mRNA) encoding SARS-CoV-2 spike (S) protein.

1 Feb 2022

Placental ACE2 shedding may block SARS-CoV-2 transmission to babies during pregnancy

While COVID-19 disease significantly impacts many pregnant women, the rates of transmission from mother to baby in pregnancy are very low.

31 Jan 2022

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

In a new study, a team of researchers discovered S-217622, a non-covalent SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate for the treatment of COVID-19.

31 Jan 2022

Prion-like domains in SARS-CoV-2 RBD and ACE2 play important functional roles in viral adhesion and entry

Scientists have recently detected and analyzed viral PrDs in the S protein of SARS-CoV-2, which are the novel regulators of virion assembly.

31 Jan 2022

Binding and conformational properties of the SARS-CoV spike protein and hACE2 complex

A new paper in the journal Molecules describes this in molecular terms, comparing SARS-CoV-2 with an earlier highly pathogenic coronavirus, SARS-CoV.

31 Jan 2022

Research shows minks mimic severe COVID-19 symptoms, including ARDS

Minks may be a suitable animal model for testing severe COVID-19 infections, finds a recent bioRxiv* preprint study. While mice and ferrets are used in preclinical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is currently no model specific to severe disease.

30 Jan 2022

Scientists evaluate zoonotic potential of NeoCoV, a coronavirus related to MERS-CoV

Researchers identify ACE2 as the functional receptor of the two close relatives of MERS-CoV, NeoCoV and PDF-2180-CoV, in bats.

30 Jan 2022

Adults and children have similar neutralizing antibody responses to SARS-CoV-2 infection

Researchers describe the kinetics of SARS-CoV-2-specific serum antibodies in convalescent children over six months following infection.

30 Jan 2022

ACE2 News and Research

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Evaluating effects of D614G and P681R/H mutations on SARS-CoV-2 VOCs

Relationship between SARS-CoV-2 neurotropism and Alzheimer's disease

Exploring human milk oligosaccharides as a method of COVID-19 prevention

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

SARS-CoV-2 omicron variant shown to replicate less efficiently in human lungs

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

Illustrating the structural diversity of SARS-CoV-2 Omicron spike

Exploring beta-coronavirus neutralization by vaccine-induced murine antibody WS6

Placental ACE2 shedding may block SARS-CoV-2 transmission to babies during pregnancy

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

Prion-like domains in SARS-CoV-2 RBD and ACE2 play important functional roles in viral adhesion and entry

Binding and conformational properties of the SARS-CoV spike protein and hACE2 complex

Research shows minks mimic severe COVID-19 symptoms, including ARDS

Scientists evaluate zoonotic potential of NeoCoV, a coronavirus related to MERS-CoV

Adults and children have similar neutralizing antibody responses to SARS-CoV-2 infection

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News